'Biomarker discovery' presentation slideshows

Ralph L. McDade, Ph.D. Strategic Development Officer

776 views • 63 slides

Translating Biomarker Discovery to Clinical Application

Translating Biomarker Discovery to Clinical Application. Sudhir Srivastava, Ph.D., M.P.H. Cancer Biomarkers Research Group. Goal: Establish a Comprehensive Approach to Biomarker Development. Discover, develop and validate biomarkers for cancer detection, diagnosis and risk assessment

682 views • 40 slides

Translating Biomarker Discovery to Clinical Application

Translating Biomarker Discovery to Clinical Application. Sudhir Srivastava, Ph.D., M.P.H. Cancer Biomarkers Research Group. Goal: Establish a Comprehensive Approach to Biomarker Development. Discover, develop and validate biomarkers for cancer detection, diagnosis and risk assessment

451 views • 40 slides

The metabonomics

472 views • 35 slides

The metabonomics

497 views • 35 slides

The metabonomics

354 views • 35 slides

Discussion Pancreatic Cancer Abstracts 145, LBA146, 147, & LBA148

Discussion Pancreatic Cancer Abstracts 145, LBA146, 147, & LBA148. Philip Agop Philip, MD, PhD, FRCP Karmanos Cancer Center Wayne State University Detroit, Michigan.

595 views • 31 slides

FP6

463 views • 29 slides

Biomarker discovery by automatic annotation of N-glycan species in MALDI-TOF-TOF spectra

Biomarker discovery by automatic annotation of N-glycan species in MALDI-TOF-TOF spectra. Chuan- Yih , Yu 2010-4-8 Capstone. Introduction. Genomics -> genomes Proteomics -> proteins Glycomics -> glycomes Post-Translation Modification (PTM) N itrosylation P hosphorylation

345 views • 20 slides

Performance and Optimization of LC-MS/MS Platforms for Unbiased Discovery of Biomarker Candidates

http://proteomics.cancer.gov. Performance and Optimization of LC-MS/MS Platforms for Unbiased Discovery of Biomarker Candidates. Daniel C. Liebler Vanderbilt University School of Medicine Vanderbilt, Tennessee.

296 views • 19 slides

COMPANION GRAPHS

COMPANION GRAPHS. Annual Global Plan Research Funding Targets vs . 2011 Investments. $800,000,000. $740,000,000. $600,000,000. $400,000,000. $420,000,000. $380,000,000. $340,000,000. $250,038,877. $200,000,000. $80,000,000. $120,361,419. $95,446,326. $84,140,175. $55,043,541. $0.

317 views • 18 slides

http://proteomics.cancer.gov

http://proteomics.cancer.gov. Experimental Design and Biospecimens. David F. Ransohoff, MD Division of Gastroenterology and Hepatology; Dept. of Medicine Department of Epidemiology, School of Public Health Director, Clinical Research Curriculum (K30) Lineberger Comprehensive Cancer Center

265 views • 15 slides

Institute for Systems Biology Moritz Lab

300 views • 11 slides

Andrew Emili Ontario Research Chair in Biomarkers of Clinical Management Donnelly Center, UofT

Biomarker Discovery. Building Personalized Medicine in Ontario. Andrew Emili Ontario Research Chair in Biomarkers of Clinical Management Donnelly Center, UofT. 2012 Symposium of Ontario Research Chairs in Public Policy Osgoode Professional Development, March 5 th , 2012.

250 views • 11 slides

Clustering of MS/MS spectra for glycan biomarker discovery

Clustering of MS/MS spectra for glycan biomarker discovery. Anoop Mayampurath , Chuan- Yih Yu. Motivation. Currently, glycomic profiles only use MS data, which give us only the general view of glycan chain in terms of abundance.

200 views • 8 slides

Metabolomics Market Is Expected To Grow At a Lucrative Rate 2023

Get PDF Sample Of Research Report: https://goo.gl/auQndT Global Metabolomics Market was valued at $1,379 million in 2016, and is estimated to reach $3,301 million by 2023, registering a CAGR of 13.2% from 2017 to 2023. Metabolomics is the study and analysis of the biochemical processes involving intermediates and byproducts of metabolic activities. These products are known as metabolomes, which reflect the cluster of all metabolites involved in various reactions in an organism, which include metabolic intermediates, signaling molecules, secondary metabolites, and hormones.

90 views • 6 slides

Metabolomics Market Size Is Projected To Be Around $2.5 Billion By 2025: Crystal Market Research

55 views • 5 slides

an introduction for Biomarker Discovery

an introduction for Biomarker Discoveryan introduction for Biomarker Discoveryan introduction for Biomarker Discoveryan introduction for Biomarker Discoveryan introduction for Biomarker Discoveryan introduction for Biomarker Discovery

30 views • 2 slides

Peptidomics analysis

Peptidomics is defined as the systematic, comprehensive, qualitative/quantitative multiplex analysis of endogenous peptides (up to ~20 kDa), in biological samples collected at a chosen time point and location. Peptidomics can complement proteomics and bridge the gap between proteomics and metabolomics. And invaluable information can be obtained from studies of the numerous soluble polypeptides, including signaling molecules (such as cytokines, growth factors, and peptide hormones), and other small protein fragments and peptides of undetermined functions, or from disease-specific proteolytic cleavage.

33 views • 2 slides

Symposium on Biomarkers in Drug Development: From Discovery to Validation in the Omic Era

Symposium on Biomarkers in Drug Development: From Discovery to Validation in the Omic Era 9 th October 2006 at the UCD Conway Institute. Registration: Coffee/tea (10.30am-11.00am) Biomarker Discovery Session (11.00am-1.00pm) Transcriptomic Approaches Used in Safety Assessment

147 views • 1 slides